Terbinafine transdermal - Crescita Therapeutics

Drug Profile

Terbinafine transdermal - Crescita Therapeutics

Alternative Names: NRI 1002; Penecure; Transcellular antifungal - Crescita

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nuvo Research
  • Developer Crescita Therapeutics
  • Class Antifungals; Naphthalenes; Small molecules
  • Mechanism of Action Cell membrane modulators; Squalene monooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Onychomycosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Onychomycosis in USA (Transdermal, Liquid)
  • 17 Aug 2015 Terbinafine transdermal is still in preclinical trials for Onychomycosis in USA (http://www.nuvoresearch.com/products/pipeline/)
  • 11 Aug 2015 Terbinafine transdermal - Nuvo Research is available for licensing as of 11 Aug 2015. http://www.nuvoresearch.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top